Prognostic value of pretreatment systemic immune-inflammation index in patients with endometrial cancer: a...

Area of Science:

• Oncology
• Immunology
• Biomarkers

Background:

• Endometrial cancer (EC) prognosis prediction is crucial for patient management.
• The systemic immune-inflammation index (SII) is an emerging biomarker.
• Evaluating SII's prognostic value in EC is warranted.

Purpose of the Study:

• To assess the systemic immune-inflammation index (SII) as a prognostic predictor for endometrial cancer (EC) patients.
• To determine the association between SII and overall survival (OS) and progression-free survival (PFS) in EC.

Main Methods:

• A meta-analysis was conducted to evaluate the prognostic role of SII in EC.
• Combined hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated.
• Statistical significance was determined using p-values.

Main Results:

• An elevated SII was significantly associated with poor overall survival in EC patients (HR = 2.01; 95% CI = 1.58-2.57; p < 0.001).
• Increased SII also predicted inferior progression-free survival in EC patients (HR = 1.87; 95% CI = 1.36-2.58; p < 0.001).

Conclusions:

• The systemic immune-inflammation index (SII) is a significant predictor of poor prognosis in endometrial cancer.
• Elevated SII scores correlate with reduced overall survival and progression-free survival.
• SII is a valuable tool for predicting both short- and long-term outcomes in EC patients.